查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466819

角膜疤痕市場:初步研究 (KOL Insights) - 市場情報 - 流行病學和 2034 年市場預測

Corneal Scarring | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
出版日期: | 出版商: Mellalta Meets LLP | 英文 113 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

角膜疤痕市場主要由外用皮質類固醇和外用絲裂黴素C貢獻。 到 2034 年，新興治療方法的採用將成為一個重大轉折點，為角膜疤痕治療市場帶來巨大變化。 2020-2034年調查期間，被調查國家（美國、法國、德國、義大利、西班牙、英國、日本）用於角膜疤痕治療的新興療法的銷售額將以3.60%的複合年增長率增長，預計將增加57億美元。

角膜疤痕，也稱為角膜白斑或角膜混濁，是一個重要的問題，因為它會影響角膜清晰度和視覺功能。 角膜高度組織化的透明結構對於其將光線傳輸到視網膜的能力至關重要，當這種結構被破壞時，就會形成疤痕組織並可能損害視力。

角膜疤痕通常是纖維化細胞反應的結果，其目的是治癒組織，但無法恢復其透明度。 這是角膜疾病和損傷的一個主要問題，因為疤痕會導致永久性視力喪失。 與其他組織相比，疤痕組織形成對角膜的影響尤其顯著，因為它直接影響視力。

本報告調查了七個主要國家的角膜疤痕市場，並提供了市場現狀、疾病概述和治療方法、患者趨勢、區域趨勢、未滿足的需求和未來前景。

目錄

第 1 章執行摘要

第2章角膜疤痕疾病的背景

  • 角膜疤痕簡介
  • 角膜混濁分級
  • 角膜疤痕的徵兆和症狀
  • 角膜疤痕的原因與危險因子
  • 角膜疤痕的病因學

第3章角膜疤痕的診斷

  • 角膜疤痕的診斷

第 4 章流行病學與病患群體

  • 主要發現
  • 方法與資料來源
    • 各國角膜疤痕診斷實例
    • 各國角膜疤痕治療實例
  • 角膜疤痕流行病學和模型參數的主要資訊來源
    • 美國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 日本

第 5 章目前的治療方法與醫療實務

  • 角膜疤痕的治療與藥物治療
  • 當前角膜疤痕的臨床藥物治療
  • 目前治療角膜疤痕的手術方法
  • 常見的角膜移植類型

第 6 章角膜疤痕患者的趨勢

  • 介紹路線
  • 診斷評估
  • 治療評估
  • 治療選擇

第 7 章美國、四個歐盟國家、英國和日本未滿足的需求

第8章新的治療方法

  • 主要發現
  • 管道概覽
  • 角膜疤痕領域的顯著進展

第9章未來治療典範

  • 角膜疤痕治療的競爭格局和預期批准
  • 未來的治療演算法與競爭定位
  • 新療法關鍵數據摘要

第 10 章當前和新治療方法的年度費用

第11章角膜疤痕後期治療的策略考量

第12章市場展望

  • 主要發現
  • 摘要
  • 2034 年之前按國家劃分的市場預測

第 13 章按國家劃分的市場預測

  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第14章市場促進因素與限制因素

第15章附錄

簡介目錄

The Corneal Scarring market is hugely contributed using topical corticosteroids and local application of mitomycin C. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the Corneal Scarring therapeutics market. The sales of the emerging therapies for the treatment Corneal Scarring in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2034 study period, adding a value estimated at a total market of $5.7 Billion by 2034.

"Depending on the depth of the scar, different surgical procedures are recommended to remove the scar. In the outer layers of the cornea, the scar may be able to be peeled or scraped away. A scar in the middle layer may be able to be removed in a laser procedure known as PTK (Photo Therapeutic Keratectomy). Corneal transplants, either full or partial, can also be performed to remove the section of the cornea containing the scar."

Corneal Scarring, also known as corneal leukoma or corneal opacity, is a significant concern due to its impact on the transparency and visual function of the cornea. The cornea's highly organized and transparent structure is crucial for its function in transmitting light onto the retina, and any disruption to this architecture can lead to scar tissue formation, impairing vision.

Scarring in the cornea is often the result of fibrotic cellular responses, which, while aiming to heal the tissue, fail to restore its transparency. This is a major concern in corneal diseases and injuries, as scarring can lead to permanent vision loss. The impact of scar tissue formation in the cornea is particularly significant compared to other tissue types, as it directly affects vision.

Mellalta's Corneal Scarring Report- Market Summary

Market Size 2034: $5.7 billion

CAGR%: 3.60%

Key Market Players: Claris Biotherapeutics

Forecast Period: 2020-2034

Countries Covered: US, France, Germany, Italy, Spain, UK, China, and Japan.

Current SOC: Topical corticosteroids; Local application of mitomycin C;

Future SOC: Hepatocyte Growth Factor (HGF)

Key Unmet Need: Standardized Treatment Guidelines; Lack of Approved Pharmaceutical Interventions; Demand for Safer and More Efficacious Treatment Options

Key Insights: Given their affordability and accessibility, current SOC therapies remain viable options for a significant portion of patients.

Provider-Patient (PPP) Perspective: Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options

Mellalta's Corneal Scarring Report - Epidemiology

The total prevalent cases of Corneal Scarring in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). This increase translates to a CAGR of approximately 0.6% over the 15-year forecast period, underscoring a steady escalation in the incidence of Corneal Scarring. As per estimates, the United States will present with the highest prevalence of Corneal Scarring cases in 2034. Among the EU5, Germany had the highest Corneal Scarring cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States.

Mellalta's Corneal Scarring Report - Current Market Size & Forecast Trends

The Corneal Scarring therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034) to USD 5.7 billion. The United States captured the highest market share as compared to the European 5 countries and Japan.

The current standard of care is limited to therapies such as prednisone acetate ophthalmic suspension, a topical corticosteroid, which is well-established for minimizing corneal scarring, leveraging its anti-inflammatory and antifibrotic properties. Corticosteroids have shown efficacy in reducing TGFb expression, which is considered a key mechanism for antifibrotic therapy in the cornea. MMC, on the other hand, is a potent mitotic inhibitor known for its chemotherapeutic applications. It works by covalently binding with DNA to inhibit synthesis processes, and as an eyedrop, it helps induce apoptosis in myofibroblasts and prevents keratocyte differentiation, playing a crucial role in the management of corneal scarring.

The complexity of treatment regimens, often involving polypharmacy with frequent dosing schedules, exacerbates compliance challenges, particularly among the working-age population where daily responsibilities may impede strict adherence. The introduction of multi agent medications could potentially streamline treatment processes, thereby improving compliance rates. Additionally, the scarcity of accessible written information on ocular chemical burns represents an informational gap that, if filled, could significantly aid in patient and caregiver understanding of the condition and its treatment. Leveraging educational resources and engaging patients' support networks are critical steps toward bolstering treatment adherence.

In the 2024-2034 forecast period, there will be tremendous growth and shift in therapeutic market with the launch of novel emerging therapies like CSB-001 (Claris Biotherapeutics) and others. The emerging therapies will likely replace existing treatments, reflecting a dynamic shift towards more advanced therapeutic options in the Corneal Scarring space and more.

Questions Answered

What is the size of clinically and commercially relevant drug-treatable Corneal Scarring populations, and how will drug-treatment rates change over time?

Potential challenges and opportunities in implementing approved therapy for Corneal Scarring.

What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?

What key drivers and constraints will affect the Corneal Scarring therapy market over the forecast period?

Report Highlights

Corneal Scarring - Current Market Trends

Corneal Scarring - Current & Forecasted Cases across the G7 Countries

Corneal Scarring - Market Opportunities and Sales Potential for Agents

Corneal Scarring - Patient-based Market Forecast to 2034

Corneal Scarring - Untapped Business Opportunities

Corneal Scarring - Product Positioning Vis-a-vis Competitors' Products

Corneal Scarring - KOLs Insight

Table of Content

1.Executive Summary

  • 1.1.Key Findings
  • 1.2.Key Market Challenges and Opportunities
  • 1.3.What Do the Experts Say?

2.Corneal Scarring Disease Background

  • 2.1.Corneal Scarring Introduction
  • 2.2.Grading of Corneal Opacities
  • 2.3.Sign and Symptoms of Corneal Scarring
  • 2.4.Causes and Risk factors of Corneal Scarring
  • 2.5.Pathogenesis of Corneal Scarring

3.Corneal Scarring Diagnosis

  • 3.1.Diagnosis of Corneal Scarring

4.Epidemiology and Patient Populations

  • 4.1.Key Findings
  • 4.2.Methods and data Sources
    • 4.2.1.Country Specific Diagnosed Prevalent cases of Corneal Scarring
    • 4.2.2.Country Specific Treated cases of Corneal Scarring
  • 4.3.Key Sources for Corneal Scarring Epidemiology and Model Parameters
    • 4.3.1.United States
      • 4.3.1.1.United States Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.1.2.United States Treated cases of Corneal Scarring
    • 4.3.2.Germany
      • 4.3.2.1.Germany Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.2.2.Germany Treated cases of Corneal Scarring
    • 4.3.3.France
      • 4.3.3.1.France Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.3.2.France Treated cases of Corneal Scarring
    • 4.3.4.Italy
      • 4.3.4.1.Italy Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.4.2.Italy Treated cases of Corneal Scarring
    • 4.3.5.Spain
      • 4.3.5.1.Spain Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.5.2.Spain Treated cases of Corneal Scarring
    • 4.3.6.United Kingdom
      • 4.3.6.1.United Kingdom Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.6.2.United Kingdom Treated cases of Corneal Scarring
    • 4.3.7.Japan
      • 4.3.7.1.Japan Diagnosed Prevalent cases of Corneal Scarring
      • 4.3.7.2.Japan Treated cases of Corneal Scarring

5.Current Therapies and Medical Practice

  • 5.1.Treatment and Medical Practices of Corneal Scarring
  • 5.2.Current clinical drug approaches to Corneal Scarring
  • 5.3.Current surgical approaches to Corneal Scarring
  • 5.4.Common types of corneal transplantations

6.Patient Journey in Corneal Scarring

  • 6.1.Referral Routes
  • 6.2.Diagnosis Evaluation
  • 6.3.Treatment Evaluation
  • 6.4.Treatment Choice

7.Unmet Needs in US, EU4, UK, and JP

8.Emerging Therapies

  • 8.1.Key Findings
  • 8.2.Pipeline Overview
  • 8.3.Notable Developments in the Corneal Scarring space
    • 8.3.1.Product Analysis
      • 8.3.1.1.CSB-001 (Claris Biotherapeutics)
        • 8.3.1.1.1.Product Profile
        • 8.3.1.1.2.Clinical Development
        • 8.3.1.1.3.Market & Sales Opportunity Forecasted to 2034
      • 8.3.1.2.Not Exhaustive list (more drugs are covered..)

9.Future Treatment Paradigm

  • 9.1.Corneal Scarring Competitor Landscape and Approvals Anticipated
  • 9.2.Future Treatment Algorithms and Competitor Positioning
  • 9.3.Key Data Summary for Emerging Treatment

10.Annual Cost of Current & Emerging Treatment

11.Late Phase Therapies Strategic Considerations in Corneal Scarring

12.Market Outlook

  • 12.1.Key Findings
  • 12.2.Overview
  • 12.3.Country Specific Market Forecast to 2034
    • 12.3.1.Country Specific Market for Corneal Scarring 2019-2034 (USD Million)
    • 12.3.2.Country Specific Market for Corneal Scarring by Therapies 2019-2034 (USD Million)

13.Market Forecast by Country

  • 13.1.United States
    • 13.1.1.United States Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.1.2.United States Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.2.Germany
    • 13.2.1.Germany Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.2.2.Germany Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.3.France
    • 13.3.1.France Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.3.2.France Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.4.Italy
    • 13.4.1.Italy Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.4.2.Italy Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.5.Spain
    • 13.5.1.Spain Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.5.2.Spain Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.6.United Kingdom
    • 13.6.1.United Kingdom Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.6.2.United Kingdom Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
  • 13.7.Japan
    • 13.7.1.Japan Market for Corneal Scarring 2019-2034 (USD Million)
    • 13.7.2.Japan Market for Corneal Scarring by Therapies 2019-2034 (USD Million)

14.Market Drivers and Constraints

    • 14.1.1.What Factors Are Driving the Market for Corneal Scarring?
    • 14.1.2.What Factors Are Constraining the Market for Corneal Scarring?

15.Appendix

  • 15.1.Methodology